Confo Therapeutics Achieves Preclinical Milestone for CFTX-2034 in Post-Bariatric Hypoglycemia Program

Confo Therapeutics' SSTR5 agonistic antibody CFTX-2034 is advancing toward IND-enabling studies following preclinical data presented at ENDO 2026, a development that signals early-stage CDMO and clinical manufacturing conversations for a metabolic indication with no currently approved therapies.

The Ghent-based biotech presented findings demonstrating that CFTX-2034 suppressed insulin and GLP-1 secretion in a dose-dependent manner, improving glycemic control without meaningfully elevating basal glucose levels. The candidate showed no cross-reactivity with related SSTR family members, supporting a selective pharmacology profile. A long half-life observed in preclinical models establishes the basis for a once-monthly subcutaneous dosing regimen, a clinically relevant differentiator for a post-surgical patient population managing ongoing glycemic instability.

Post-bariatric hypoglycemia affects a subset of patients following bariatric surgery and presents as dangerous postprandial blood glucose drops that can progress to cognitive impairment, loss of consciousness, or seizure. No FDA-approved or EMA-approved treatment currently exists for the condition, leaving clinicians reliant on dietary modification and off-label interventions. CFTX-2034's mechanism, selective SSTR5 agonism to modulate insulin and incretin secretion, represents a distinct pharmacological approach to restoring glycemic control in this population.

Confo's CSO, Dr. Christel Menet, presented the data in Chicago on June 15, 2026. The company also noted that CFTX-2034 may be compatible with GLP-1 agonists already used by many post-bariatric patients for continued weight management, a combination-use consideration that will carry weight in future clinical protocol design and labeling discussions.

For manufacturing and regulatory teams tracking the metabolic pipeline, the transition into IND-enabling studies marks the point at which process development, analytical method qualification, and GMP batch production planning typically begin in earnest. Confo's platform relies on conformation-specific ConfoBodies to stabilize GPCRs during discovery, a biologics-derived modality that will require antibody-specific manufacturing infrastructure and CMC documentation aligned with ICH Q11 and relevant biologics guidance under 21 CFR Part 600.

The IND-enabling timeline will serve as the first measurable checkpoint for partners and contract manufacturers assessing entry into Confo's CFTX-2034 program.

Source: Confo Therapeutics via GlobeNewswire, June 15, 2026. Data presented at the Endocrine Society's Annual Meeting (ENDO 2026), Chicago, Illinois, June 13–16, 2026.